Updated: Athira plots an Alzheimer's comeback after scandal, PhII fail — and hints at possible accelerated approval pitch
Athira Pharma built up high hopes for its alternative approach to developing Alzheimer’s treatments, but a scandal involving doctored images, a very public board fight and a Phase II fail took the wind out of its sails. On Tuesday, the company outlined an attempted path forward.
Following an exploratory study looking at long-term effects that researchers note also failed its primary goal, Athira plans to amend its Phase II trial and include new measurements on cognition, function and neurodegeneration. The primary endpoint will remain the same, but Athira will closely scrutinize its drug, fosgonimeton, in patients who aren’t using another kind of therapy to treat Alzheimer’s-related dementia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.